Business Context and Reporting Period
Daré Bioscience, Inc. (DARE) filed this Form 8-K on July 18, 2025, to report an "Other Event" regarding its compliance status with Nasdaq listing requirements. The company has been non-compliant with Nasdaq Listing Rule 5550(b) since August 2024 due to insufficient stockholders' equity.
Key Financial Metrics
- Capital Raised: Approximately $16.5 million in gross proceeds from sales of common stock under its "at-the-market" (ATM) equity offering program between March 31, 2025, and July 18, 2025.
- Stockholders' Equity: Management believes equity is now in excess of the $2.5 million minimum required under Nasdaq Listing Rule 5550(b)(1), after accounting for anticipated losses through July 18, 2025.
- Shares Outstanding: Approximately 12.6 million shares of common stock outstanding following the recent sales.
- Revenue, Profit, and Cash Flow: The filing text does not provide specific values for revenue, net income, operating cash flow, or margins.
- Debt and Liquidity: The filing text does not provide specific values for debt levels or total liquidity beyond the proceeds mentioned.
Material Changes
The primary material change is the increase in stockholders' equity resulting from the ATM offering, which the company believes restores compliance with the $2.5 million equity threshold. This contrasts with the prior status of non-compliance held since August 2024.
Outlook, Risks, and Management Commentary
Management intends to notify Nasdaq of the regained equity levels to request a determination of continued listing compliance. However, the company explicitly states there can be no assurance that Nasdaq will determine the company has regained compliance. Risks include the possibility of continued non-compliance and the ongoing need to raise additional capital to maintain listing standards. The filing includes standard forward-looking statement disclaimers regarding uncertainties in achieving these outcomes.
Investor Verification Checklist
- Confirm whether Nasdaq has officially accepted the company's notification and granted compliance status.
- Verify the exact net stockholders' equity figure in the most recent financial statements to ensure it exceeds the $2.5 million threshold after all losses.
- Review the company's ability to sustain equity levels without further dilution or capital raises.
- Check for any subsequent filings regarding the status of the ATM program or additional equity sales.